Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical and Orexigen Therapeutics have launched Contrave (naltrexone HCI and bupropion HCI) extended-release tablets in the US and will be available to patients by prescription.
Subscribe to our email newsletter
The US Food and Drug Administration (FDA) has approved Contrave as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30kg/m2 or greater, or 27kg/m2 or greater in the presence of at least one weight-related comorbid condition.
Takeda Pharmaceuticals USA president Douglas Cole said the company is happy that Contrave is now available and that they are able to provide eligible patients with additional offerings.
"These offerings include the Scale Down program, a support program for weight management, and Contrave Direct Save, which helps eligible patients to get Contrave at the lowest cost available to them, which can help to support a patient’s complete approach to weight management," Cole said.
The company said that eligible patients taking Contrave will have access to the Scale Down program, which offers mobile weight management support with a wireless scale that triggers daily personalized texts based on weigh-ins.
Takeda and Orexigen entered into a collaboration agreement in September 2010 to develop and commercialize Contrave in the US, Canada and Mexico.